EFPIA & CRA：2024年创新药物不可及和延迟上市的根本原因分析报告（英文版）（41页）.pdf

1、The root causes of unavailability of innovative medicines and delays in access June 2024 Page 1 The root causes of unavailability of innovative medicines and delay in access:Shortening the wait Executive Summary1 The unprecedented speed of innovation exhibited over the last five years and the promis

2、e of the industry pipeline2 provide an important opportunity to improve outcomes for patients.There is common agreement that the value of innovation is realised only when patients benefit from advances in treatment.However,a significant number of medicines are not available across all European Union

3、(EU)markets.3 EFPIA has for many years looked at the length of time it takes for medicines to be made available.As illustrated by the most recent data in the Patient W.A.I.T.Indicator Survey in 2023,the average time to reimbursement for innovative treatments across EU and European Economic Area coun

4、tries has reached 531 days,ranging from 126 days in Germany to 990 days in Turkey.4 There are patient access inequities within Europe,with significant differences across countries in the number of products available at any given time and that the time taken prior to national reimbursement also varie

5、s significantly from one country to another.The industry shares concern about these delays and recognise that delays and the unavailability of medicines harm patients.These concerns are important context for the debate regarding the impact of the EUs General Pharmaceutical Legislation and whether it

6、 will improve access to medicines for patients in the EU.Over the past four years,EFPIA has documented the root causes of access inequality and found 10 interrelated factors that explain unavailability and delay(defined as length of time from European marketing authorisation to availability at the m